Home
 /
Papers
 /
Biochemistry
 /
Molecular mechanism of naturally-encoded signaling-bias at the complement anaphylatoxin receptors
Preprint
Open access
V1
Top 1% · Validated by QED

Molecular mechanism of naturally-encoded signaling-bias at the complement anaphylatoxin receptors

Divyanshu Tiwari, Kazuhiro Sawada, Annu Dalal +26 more
November 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.11.01.685996
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Biochemistry this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By revealing that nature encodes transducer selectivity directly into endogenous ligands and receptor architecture, this work overturns the assumption that biased GPCR signaling is primarily a synthetic pharmacology phenomenon, opening new avenues for physiologically grounded therapeutic design.

QED claims analysis

Summary

Naturally-encoded signaling bias at complement anaphylatoxin receptors arises through two distinct mechanisms: C5a-d-Arg acts as a G-protein-biased agonist at C5aR1 by inducing altered TM7 and helix 8 conformations that impair GRK recruitment and receptor phosphorylation, while C5aR2 exhibits intrinsic β-arrestin bias through a wider, more hydrophobic cytoplasmic cavity with shortened transmembrane helices, altered intracellular loops, and modified conserved motifs that collectively prevent efficient G-protein coupling.

See full analysis
Main Claim 1 –

C5a-d-Arg Is a Naturally Encoded G-Protein-Biased C5aR1 Agonist

Supporting evidence

  • C5a-d-Arg Bias Alters Primary-Cell Responses and In Vivo Outcomes
  • Plasma-Derived C5a-d-Arg Recapitulates Recombinant Ligand Bias
  • C5a-d-Arg Reduces Neutrophil Mobilization In Vivo
Main Claim 2 –

C5a-d-Arg Bias Arises from TM7/H8 Changes Reducing GRK Phosphorylation

Supporting evidence

  • Loss of Asp2827.35 Contact Shifts C5aR1 Dynamics with C5a-d-Arg
  • Orthosteric Mutations Disproportionately Impair C5a-d-Arg Signaling
  • C5a-d-Arg Specifically Reorients C5aR1 TM7 and Helix 8
  • HDX-MS Shows Stronger C5a Than C5a-d-Arg Stabilization
  • C5a-d-Arg Strongly Reduces GRK Recruitment to C5aR1
  • Reduced GRK Recruitment Lowers C5aR1 Phosphorylation with C5a-d-Arg
Main Claim 3 –

C5aR2 Is β-Arrestin-Biased and Responds Equally to C5a

Main Claim 4 –

C5a Binding Drives Active-Like Canonical 7TM Conformation in C5aR2

Supporting evidence

  • C5a Engages C5aR2 Differently Than C5aR1
  • HDX-MS Confirms C5a-Induced Conformational Changes in C5aR2
  • Mouse C5aR2 Forms Disulfide-Linked Covalent Dimers
  • C5a-d-Arg Retains C5aR2 Activity via Redistributed Contacts
  • Mutagenesis Confirms Distinct C5a Binding Determinants in C5aR1 vs C5aR2

Abstract

The conceptual framework of biased signaling has revolutionized our understanding of GPCR signaling and regulatory paradigms, and greatly impacted the efforts focused on the discovery of GPCR-targeted therapeutics. However, the mechanistic basis of biased signaling remains primarily defined based on synthetic ligands and receptor mutants with relatively limited progress in understanding naturally-encoded signaling-bias. Here, we present fundamental molecular and structural insights into naturally-encoded signaling-bias at the complement anaphylatoxin C5a receptors namely, C5aR1 and C5aR2. We first discover that C5a-d-Arg, the naturally-occurring version of C5a lacking the terminal arginine, exhibits robust G-protein signaling-bias at C5aR1, characterised by attenuated βarr recruitment. This signaling-bias manifests in both cytokine release from primary human immune cells, and in vivo, during neutrophil mobilization. We combine the cryo-EM structures of C5a/C5a-d-Arg-C5aR1 complexes with MD simulation, site-directed mutagenesis, and cellular experiments to elucidate that the G-protein-bias exhibited by C5a-d-Arg results from a distinct orientation of TM7 and helix 8 in C5aR1 leading to inefficient GRK recruitment and receptor phosphorylation. Next, we determine the first cryo-EM structures of C5aR2, a naturally-encoded β-arrestin-biased receptor, in an apo state, complexed with the natural agonists C5a and C5a-d-Arg, and three peptide agonists including a first-in-class, newly discovered C5aR2-selective agonist, R8Y. These structural snapshots reveal key differences between the binding of C5a and C5a- d-Arg to C5aR1 and C5aR2, and provide a molecular basis of functional specialization at these two receptors. Moreover, the structural insights also allow us to decipher the molecular basis of naturally-encoded signaling-bias at C5aR2 originating from a shallower cytoplasmic interface with hydrophobic interior pocket that is not permissive to efficient G-protein-coupling and activation. Finally, we also engineer and characterize loss-of-function and gain-of-function variants of C5aR1 and C5aR2, which in turn corroborate and validate the structural observations presented here. Collectively, our findings offer crucial insights into previously lacking molecular mechanisms of the naturally-encoded signaling-bias at GPCRs, which have broad implications not only for the general framework of biased-signaling, but also for novel therapeutic design.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?